TY - JOUR
T1 - Effects of nattokinase on blood pressure
T2 - A randomized, controlled trial
AU - Kim, Ji Young
AU - Gum, Si Nae
AU - Paik, Jean Kyung
AU - Lim, Hyo Hee
AU - Kim, Kyong Chol
AU - Ogasawara, Kazuya
AU - Inoue, Kenichi
AU - Park, Sungha
AU - Jang, Yangsoo
AU - Lee, Jong Ho
PY - 2008
Y1 - 2008
N2 - The objective of this study was to examine the effects of nattokinase supplementation on blood pressure in subjects with pre-hypertension or stage 1 hypertension. In a randomized, double-blind, placebo-controlled trial, 86 participants ranging from 20 to 80 years of age with an initial untreated systolic blood pressure (SBP) of 130 to 159 mmHg received nattokinase (2,000 FU/capsule) or a placebo capsule for 8 weeks. Seventy-three subjects completed the protocol. Compared with the control group, the net changes in SBP and diastolic blood pressure (DBP) were -5.55 mmHg (95% confidence interval [CI], -10.5 to -0.57 mmHg; p<0.05) and -2.84 mmHg (CI, -5.33 to -0.33 mmHg; p<0.05), respectively, after the 8-week intervention. The corresponding net change in renin activity was -1.17 ng/mL/h for the nattokinase group compared with the control group (p<0.05). In conclusion, nattokinase supplementation resulted in a reduction in SBP and DBP. These findings suggest that increased intake of nattokinase may play an important role in preventing and treating hypertension.
AB - The objective of this study was to examine the effects of nattokinase supplementation on blood pressure in subjects with pre-hypertension or stage 1 hypertension. In a randomized, double-blind, placebo-controlled trial, 86 participants ranging from 20 to 80 years of age with an initial untreated systolic blood pressure (SBP) of 130 to 159 mmHg received nattokinase (2,000 FU/capsule) or a placebo capsule for 8 weeks. Seventy-three subjects completed the protocol. Compared with the control group, the net changes in SBP and diastolic blood pressure (DBP) were -5.55 mmHg (95% confidence interval [CI], -10.5 to -0.57 mmHg; p<0.05) and -2.84 mmHg (CI, -5.33 to -0.33 mmHg; p<0.05), respectively, after the 8-week intervention. The corresponding net change in renin activity was -1.17 ng/mL/h for the nattokinase group compared with the control group (p<0.05). In conclusion, nattokinase supplementation resulted in a reduction in SBP and DBP. These findings suggest that increased intake of nattokinase may play an important role in preventing and treating hypertension.
UR - http://www.scopus.com/inward/record.url?scp=55449090425&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=55449090425&partnerID=8YFLogxK
U2 - 10.1291/hypres.31.1583
DO - 10.1291/hypres.31.1583
M3 - Article
C2 - 18971533
AN - SCOPUS:55449090425
SN - 0916-9636
VL - 31
SP - 1583
EP - 1588
JO - Hypertension Research
JF - Hypertension Research
IS - 8
ER -